hormone receptor positive

Questions discussed in this category

What adjuvant therapy would you recommend for a 90-year-old woman with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2019-02-14

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Related Topics